LAVAL, Quebec, Jan. 30, 2013 (GLOBE NEWSWIRE) -- Neptune Technologies & Bioressources Inc. (" Neptune") (Nasdaq.NEPT) (TSX:NTB) announces that it has filed a complaint under Section 337 of the US Tariff Act of 1930 (the "Complaint") with the United States International Trade Commission (the "ITC") alleging that Aker BioMarine AS, Aker BioMarine Antarctic USA, Inc., Aker BioMarine Antarctic AS, Enzymotec Limited, Enzymotec USA, Inc., Olympic Seafood AS, Olympic Biotec Ltd., Rimfrost USA, LLC, Bioriginal Food & Science Corp. and Avoca, Inc., a division of Pharmachem Laboratories Inc. (the "Respondents") are engaging in unfair trade practices by, at least, the importation, sale for importation, and sale after importation of certain krill-based products, namely krill paste and krill oils, that directly or indirectly infringe one or more claims of Neptune's U.S. Patent No. 8,278,351 (" the '351 Patent").
"Neptune's patent estate reflects its position as the pioneer and market leader in the field. The filing of the Complaint is consistent with our philosophy that infringing competitors must be held accountable for their actions," said Mr. Henri Harland, Neptune's CEO and President. "This approach will enhance our business position as the leader and the innovator in this market."
Neptune is seeking an order prohibiting the Respondents, their subsidiaries, related companies and agents from engaging in the importation, sale for importation, marketing and/or advertising, distribution, offering for sale, sale, sale after importation, or other transfer within the United States of certain krill-based products that infringe one or more claims of the '351 Patent. Neptune expects that the ITC investigation will formally commence within the next month or so, and that the case will take a total of about 15 to 18 months to conclude."The ITC is one of the fastest means for judicial resolution of a patent dispute in the United States and it has the power to issue broad and severe remedies," added Mr. Harland. "When a company infringes our patents, without our permission or a license, we owe it to our shareholders and investors to protect the patents through every means available to us," he concluded.